Related Experiment Video
Updated: Sep 28, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
NF-κB and EGFR participate in S1PR3-mediated human renal cell carcinomas progression
Yali Yan1, Gegentuya Bao1, Jingyuan Pei1
1The State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, Inner Mongolia, China.
Abstract:
The bioactive lipid sphingosine 1-phosphate (S1P) is implicated in many pivotal processes for the physiological and pathological actions via activating five types of G-protein-coupled S1P receptors (S1PR1-5). The role of S1P in renal cell carcinoma (RCC) and its receptor subtype specific mediating mechanism are poorly studied. So we focus on the regulatory role of S1P in RCC progression and the receptor subtypes involved in S1P-induced actions, intending to further clarify a novel therapeutic target for RCC. Analysis of The Cancer Genome Atlas (TCGA) databases showed that the patients with high expression of S1PR3 had significantly worse overall than with low expression. We further demonstrated that S1P could promote proliferation, migration, and epithelial-mesenchymal transition (EMT) of renal cancer cells in vitro, and the actions were enhanced with the increase of S1PR3 expression. Meanwhile, the results in animal experiments also showed that S1PR3 could accelerate tumorigenesis and metastasis of RCC. Our study also clarified the mechanism for S1P induced cell proliferation is mediated by S1PR3/Gi/p38/Akt/p65/cyclin D1-CDK4 pathway and the main pathway for migration is S1PR3/Gi/q/ERK/p38/p65. In addition, S1PR3 was involved in epidermal growth factor (EGF)-induced actions by enhancing protein expression, not by transactivation of epidermal growth factor receptor (EGFR). These results also further supported our conclusion that the carcinogenic role of S1P/S1PR3 axis. Thus, our findings provide that S1PR3 may be a promising small molecular therapeutic target for S1PR3 expressed cancers.
Insights
Sphingosine 1-phosphate (S1P) promotes renal cell carcinoma (RCC) progression and metastasis by activating S1PR3. Targeting the S1P/S1PR3 axis offers a potential therapeutic strategy for RCC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Sphingosine 1-phosphate (S1P) is a bioactive lipid involved in numerous physiological and pathological processes through its receptors (S1PR1-5).
- The specific role of S1P and its receptor subtypes in renal cell carcinoma (RCC) pathogenesis remains largely unelucidated.
- Understanding these mechanisms is crucial for identifying novel therapeutic targets in RCC.
Purpose of the Study:
- To investigate the regulatory role of S1P in RCC progression.
- To identify the specific receptor subtypes mediating S1P-induced effects in RCC.
- To evaluate the S1P/S1PR3 axis as a potential therapeutic target for RCC.
Main Methods:
- Analysis of The Cancer Genome Atlas (TCGA) patient databases.
- In vitro studies assessing the effects of S1P on renal cancer cell proliferation, migration, and epithelial-mesenchymal transition (EMT).
- In vivo animal experiments to evaluate the impact of S1PR3 on RCC tumorigenesis and metastasis.
- Mechanistic studies to elucidate signaling pathways involved in S1P/S1PR3-mediated effects.
Main Results:
- High S1PR3 expression in RCC patients correlates with significantly worse overall survival.
- S1P promotes renal cancer cell proliferation, migration, and EMT, with effects amplified by increased S1PR3 expression.
- S1PR3 accelerates RCC tumorigenesis and metastasis in animal models.
- Identified key signaling pathways: S1PR3/Gi/p38/Akt/p65/cyclin D1-CDK4 for proliferation and S1PR3/Gi/q/ERK/p38/p65 for migration.
- S1PR3 enhances epidermal growth factor (EGF)-induced effects by increasing protein expression, not EGFR transactivation.
Conclusions:
- The S1P/S1PR3 axis plays a significant carcinogenic role in RCC.
- S1PR3 is a promising molecular target for developing novel small molecule therapies for S1PR3-expressing RCC.
- Targeting S1PR3 may offer a new therapeutic avenue for patients with advanced or metastatic renal cell carcinoma.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Mitogens and the Cell Cycle
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway

